Welcome to our dedicated page for Covalon Technologies news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on Covalon Technologies stock.
Covalon Technologies Ltd. (CVALF) is described in its news releases as an advanced medical technologies and medical device company with expertise in advanced wound care, vascular access, and surgical consumables. The Covalon news flow often combines clinical, commercial, and financial updates, giving investors and healthcare professionals insight into how its technologies are being adopted and how the business is performing.
Recent announcements include detailed financial results, where the company has reported multiple years of revenue growth, profitability, and a debt-free balance sheet, as well as the declaration and payment of its first-ever special cash dividend. These financial updates are accompanied by commentary on revenue by product category and sales channel, including U.S. Vascular Access and Surgical Consumables, U.S. Advanced Wound Care, and International channels.
Covalon’s news also highlights clinical milestones and conference activity. The company has announced a peer-reviewed study in the Journal of the Association for Vascular Access evaluating its VALGuard ae Vascular Access Line Guard in pediatric central line care, with reported reductions in CLABSI rates. It regularly reports on participation in major professional meetings such as the Association for Vascular Access Annual Scientific Meeting, the Association of Pediatric Hematology/Oncology Nurses Conference, and the ANCC National Magnet & Pathway to Excellence Conference, where it showcases VALGuard ae, CovaClear ae, IV Clear ae, and SurgiClear ae dressings.
Investors following CVALF news can expect updates on quarterly and annual financial results, dividend decisions, board and executive changes, new clinical evidence, health economic findings, and Covalon’s presence at investor conferences such as the Planet MicroCap Showcase. This combination of financial, clinical, and market-facing news provides context on how the company positions its technologies and on the evolution of its business across its key sales channels.
Covalon Technologies (TSXV:COV, OTCQX:CVALF), an advanced medical technologies company, will be presenting at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024, at 10:00 AM PST. Brent Ashton, CEO of Covalon, will host the presentation and answer questions.
The live presentation can be accessed via webcast at https://www.webcaster4.com/Webcast/Page/3056/510941. One-on-one meetings will be conducted in person at the Fairmont Waterfront Vancouver. If unable to attend live, the presentation will be available on the conference event platform under the 'Agenda' tab at https://planetmicrocapshowcase.com/agenda.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) reported strong Q3 fiscal 2024 results, with significant year-on-year growth. Key highlights include:
- Q3 revenue of $9.2 million, up 47% year-on-year
- Q3 gross profit of $5.4 million, up 51% year-on-year
- Q3 EBITDA of $1.7 million and adjusted EBITDA of $2.4 million
- Earnings per share (EPS) of $0.06
The company's performance was driven by expansion in US hospitals and stronger demand for its collagen dressing. Gross margin improved to 59%, while operating expenses decreased due to restructuring efforts. The company's CEO, Brent Ashton, emphasized that these results demonstrate progress on key priorities and the success of foundational work to strengthen Covalon.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced it will release its Q3 Fiscal 2024 financial results on Wednesday, August 21, 2024, before markets open. The company will hold a conference call and webcast to discuss these results on the same day at 8:30am ET.
Participants can join the webcast or dial in to the conference call using the provided links and numbers. The call will include a Q&A session where participants can ask questions to Company management. A recording of the call will be available on Covalon's website under the Investors tab. Financial statements and MD&A can be accessed on SEDAR PLUS and the company's website.
Covalon Technologies announced strong Q2 fiscal 2024 results, with a 16% year-on-year revenue increase to $8.4 million. The company achieved an EBITDA of $1.7 million, adjusted EBITDA of $2.5 million, and an EPS of $0.06. US product segment revenue surged by 54%, contributing to the overall growth. Gross margins improved to 63%, the highest in recent company history. Operating expenses were reduced by 22% compared to the previous year, further boosting profitability. Additionally, the company noted a significant reduction in development and consulting services revenue to $0.06 million for the half-year period, down 97% from the prior year. A conference call to discuss these results is scheduled for May 29, 2024.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) will release its Q2 Fiscal 2024 financial results on May 29, 2024, before markets open. A conference call and webcast to discuss these results will be held the same day at 8:15am ET. Participants can join the call by dialing the provided phone numbers or access the live webcast via a link. The conference call will include a Q&A session where management will answer questions. A recording will be available on the Covalon website. Financial statements and MD&A can be accessed on SEDAR PLUS and Covalon’s website.
Covalon Technologies announced its participation in the Infusion Nurses Society Annual Meeting and Exhibition in Kansas City from May 18 to May 20, 2024. At booth #420, Covalon will showcase its advanced vascular access and infection control solutions, including VALGuard, IV Clear, and CovaClear IV. These products emphasize comfort, protection, and patient safety during infusion treatments. CEO Brent Ashton highlighted the company's dedication to combining efficacy and empathy in patient care.
Summary not available.
Summary not available.
Summary not available.
Summary not available.